Date clarification: GE HealthCare is scheduled to report today, Wednesday, July 29, 2026, with its earnings call at 8:30 a.m. ET—not tomorrow. Importantly, the company already preannounced selected preliminary 2Q results on July 23.
GEHC has already indicated that 2Q26 revenue grew 5.7% reported and 3.5% organically, while adjusted EPS grew year over year and came in above its prior expectation. It also reaffirmed full-year guidance. That makes the upcoming release less about whether GEHC clears the basic quarterly bar and more about:
The setup appears incrementally favorable following the preannouncement, but a large positive stock reaction may require evidence that the quarter’s upside is operational—not merely timing, FX, or discrete cost benefits—and that the back-half earnings ramp remains credible.
| Preliminary 2Q26 item | Disclosure | Takeaway |
|---|---|---|
| Revenue | $5.295B, +5.7% YoY | Above the $5.007B reported in 2Q25 |
| Organic revenue growth | +3.5% | In line with management’s prior 2Q outlook of +3% to +4% |
| Adjusted EPS | Up YoY; above prior expectation | Meaningfully better than prior guidance for a low-single-digit YoY decline |
| FY26 guidance | Reaffirmed | No change to sales, margin, EPS, or free-cash-flow outlook |
The EPS commentary is the material positive. GEHC had previously anticipated a low-single-digit year-over-year adjusted-EPS decline in 2Q, versus $1.06 in 2Q25. The preliminary update therefore implies adjusted EPS of at least roughly $1.07, although the company has not yet provided the exact figure.
Management entered the year with constructive end-market commentary: healthy capital-equipment demand, a record $21.8B backlog exiting 1Q, and a 1.07x book-to-bill ratio. The concern was not demand; it was profitability.
In 1Q26, GEHC reported 2.9% organic revenue growth but only a 13.5% adjusted EBIT margin, down 150 basis points year over year. The miss reflected tariffs, weaker PCS volume, and a discrete Pharmaceutical Diagnostics supplier-quality issue. The supplier issue was said to be resolved, leaving cost inflation and execution in PCS as the more enduring near-term questions.
The 2Q preannouncement suggests commercial execution held up: organic growth accelerated from 2.9% in 1Q to 3.5% in 2Q. Investors now need confirmation that better-than-expected EPS was driven by underlying price/cost actions, volume mix, and improved execution rather than temporary items.
This is likely the single most important operational disclosure.
GEHC’s 1Q organic orders rose only 1.1%, albeit against a difficult 10.3% prior-year comparison. Management nevertheless described capital-equipment markets as healthy and expected a stronger second half, supported by backlog conversion, new products, and PCS monitoring-installation timing.
What would be constructive - Organic order growth that reaccelerates from 1Q levels - Book-to-bill at or above 1.0x - Evidence that large PCS monitoring projects are proceeding as planned - Confirmation that Imaging/AVS demand remains strong across the U.S., EMEA, and Rest of World
What would concern investors - Orders lagging revenue materially - Any slippage in PCS installations or backlog conversion - A more cautious demand outlook in China or among hospital capital budgets
GEHC reaffirmed its FY26 outlook:
| FY26 guidance | Current outlook |
|---|---|
| Organic revenue growth | +3% to +4% |
| Adjusted EBIT margin | 15.4% to 15.7% |
| Adjusted EPS | $4.80 to $5.00 |
| Free cash flow | ~$1.6B |
| Adjusted tax rate | 20% to 21% |
A maintained guide after a better-than-expected 2Q EPS result is constructive, but it also signals that management is retaining caution around the second half. The full-year range requires a sizable earnings step-up after the first half, given 1Q adjusted EPS of $0.99 and the company’s prior expectation for a softer 2Q.
The key question for the call: Is the 2Q upside a reason to raise the floor of guidance, or simply a buffer against still-elevated 2H uncertainty?
At 1Q earnings, GEHC reduced its FY26 profit outlook because it expected approximately $250M of gross inflation pressure, largely tied to memory chips, oil/freight, and other commodities. Management expected to offset more than half through pricing and cost measures, but noted that these actions would contribute much more in the second half.
The company also said in 1Q that: - 2Q would be the first quarter with meaningful inflation impact; - the largest gross cost effect would occur in 3Q and 4Q; - most offset actions would begin benefiting results in the second half.
Accordingly, investors should focus less on 2Q margin in isolation and more on management’s confidence in its 3Q–4Q price/cost offsets. A reaffirmation of the EBIT-margin guide is helpful; specific evidence on pricing realization, freight actions, and memory-cost assumptions would be more important.
PCS was the weak point in 1Q:
Management attributed the weakness primarily to timing of larger monitoring installations, which were expected to be more second-half weighted, along with tariff pressure. It also anticipated a U.S. clearance for a new premium anesthesia product in 3Q.
For 2Q, investors should look for: - Stabilization in PCS revenue and orders; - Progress on backlog conversion; - Commentary on the new anesthesia product’s regulatory timing; - Evidence that pricing and cost-structure initiatives are improving profitability.
A PCS recovery is central to the back-half growth and margin thesis. Continued underperformance would make the full-year margin guide more difficult to defend.
PDx delivered 9.7% organic growth in 1Q, driven by contrast media, pricing, and radiopharmaceuticals. Flyrcado continued to ramp: management cited approximately 390 doses in the week ended April 17, 2026, and reiterated a goal of at least $500M in annual revenue by 2028.
Items to watch: - Flyrcado dose growth, customer additions, CMO reliability, and reimbursement/workflow adoption; - Vizamyl growth tied to broader use of Alzheimer’s disease-modifying therapies; - The resolved supplier issue’s residual impact; - Any update on generic competition in contrast media.
PDx margin was pressured in 1Q by the supplier issue, investment in radiopharmaceuticals, and the Nihon Medi-Physics acquisition. A clean 2Q margin progression would help validate that the 1Q weakness was largely transitory.
GEHC is combining its former Imaging and Advanced Visualization Solutions businesses into Advanced Imaging Solutions (AIS), with recast financials expected alongside 2Q reporting.
This is strategically relevant because the company is positioning AIS around integrated clinical pathways, AI-enabled imaging, and a stronger commercial/technology focus. Investors should watch for: - The newly disclosed AIS growth and margin profile; - Incremental cost-synergy expectations; - Adoption commentary around Vivid Pioneer, Revolution Vibe, and Photonova Spectra photon-counting CT; - The commercial funnel and timing for photon-counting CT, where revenue contribution is expected to be more meaningful in 2027 rather than 2026.
The innovation pipeline is a medium-term upside rather than a major 2Q revenue driver. The near-term question is whether it is already supporting orders, mix, and pricing.
On July 23, GEHC announced that CFO Jay Saccaro will leave on August 14, 2026 for a role outside the medical-technology industry. Controller and Chief Accounting Officer George Newcomb will become interim CFO while the company conducts a search.
The timing is not ideal: Saccaro has been closely associated with GEHC’s financial discipline, capital allocation, tariff mitigation, and post-spin operating framework. Still, Newcomb has been GE HealthCare’s controller since 2016 and chief accounting officer since the 2023 separation, which should reduce continuity risk.
The call should clarify: - Whether the departure is purely career-driven; - The expected timeline and profile for a permanent successor; - Whether the company’s capital-allocation priorities or financial framework will change.
Absent broader signs of disruption, this should be a governance overhang rather than a change in the operating thesis.
GEHC closed at $64.13 on July 28, essentially unchanged from $64.01 on June 30. The shares fell to $60.58 on July 24—immediately after the preliminary-results/CFO-transition announcement—but subsequently recovered nearly 6% into the report.
That trading pattern suggests investors have begun to separate the favorable preliminary results from the leadership-transition concern. Still, because revenue growth, organic growth, EPS direction, and FY guidance have already been disclosed, the stock’s reaction will likely hinge on the unreported details: orders, margins, segments, cash flow, and 2H confidence.
Constructive near-term setup, but the report must validate a back-half execution story. GEHC has already removed much of the risk around the 2Q headline: organic growth was in range, adjusted EPS beat its prior outlook, and FY guidance was maintained. The investment debate now shifts to whether the company can translate solid end-market demand and innovation momentum into margin recovery despite inflation, tariffs, and a weak PCS starting point.
What specifically gives management confidence that the planned 3Q–4Q margin and EPS acceleration will occur, and how much of the 2Q EPS upside is sustainable?
Sources: GE HealthCare’s 1Q26 earnings release and call materials dated April 29, 2026; preliminary 2Q26 results and CFO-transition disclosure dated July 23, 2026; GE HealthCare’s 2Q25 earnings release; historical GEHC share-price data through July 28, 2026.